

## Netcare Medical Scheme Oncology Innovation Benefit Brochure 2026

### Who we are

Netcare Medical Scheme (referred to as 'the Scheme'), registration number 1584, is a not-for-profit organisation, registered with the Council for Medical Schemes.

Discovery Health (Pty) Ltd (referred to as "the Administrator"), is a separate company and an authorised financial services provider (registration number 1997/013480/07. We take care of the administration of your membership for the Scheme.

### Contact details

You can call us on 0861 638 633 or visit [www.netcaremedicalscheme.co.za](http://www.netcaremedicalscheme.co.za) for more information.

### Overview

The Oncology Innovation Benefit gives members access to a defined list of high-cost medicines and new technologies for a defined list of cancers.

### About some terms we use in this document

Terminology	Description
<b>Co-payment</b>	This is an amount that you need to pay towards a healthcare service. The amount can vary by the type of covered healthcare service, place of service or if the amount the healthcare professional charges is higher than the rate we cover. If the benefit co-payment or upfront amount is higher than the amount charged for the healthcare service, you will have to pay for the cost of the healthcare service.
<b>Designated Service Provider (DSP)</b>	A healthcare professional or group of healthcare professionals contracted by the Scheme as a preferred provider to provide diagnosis, treatment and/or care to beneficiaries in respect of one or more Prescribed Minimum Benefit (PMB) condition/s.
<b>Netcare Medical Scheme Rate</b>	The Rate at which health services are reimbursed by the Scheme in accordance with the applicable benefit schedule and determined by the Scheme from time to time.

## Cover from the Oncology Innovation Benefit

The Oncology Innovation Benefit provides you with cover for a defined list of cancers and precision medicine, subject to the Scheme's clinical entry criteria.

Approval is subject to meeting clinical entry criteria and requests may be reviewed by an external panel for consideration for funding from this benefit.

We will pay up to 75% of the Netcare Medical Scheme Rate. If the healthcare professional charges more than the amount the Scheme pays, you will need to pay the difference. This amount could be more than 25% if your treatment cost is above the Netcare Medical Scheme Rate.

## Defined medicines are covered from the Oncology Innovation Benefit

If you meet the Scheme's clinical entry criteria, you have cover for the following oncology medicines:

Indication	Product Name	Clinical Criteria
Locally Advanced or Metastatic non-small cell lung cancer	Keytruda solution for infusion vial 4ml	Metastatic non-small cell lung carcinoma (NSCLC) and as first line therapy and whose tumours express PD-L1 with a $\geq 50\%$ and with no EGFR or ALK genomic tumour aberrations
	Keytruda solution for infusion vial 4ml	Metastatic Squamous non-small cell lung carcinoma (NSCLC) and in combination with carboplatin and either paclitaxel or nab-paclitaxel and as first line therapy
	Keytruda solution for infusion vial 4ml	Metastatic non-squamous non-small cell lung carcinoma (NSCLC) and in combination with pemetrexed and platinum chemotherapy and as first line therapy and with no EGFR or ALK genomic tumour aberrations
	Keytruda solution for infusion vial 4ml	Advanced non-small cell lung carcinoma (NSCLC) as second line



Medical Scheme  
Administered by Discovery Health

		therapy after platinum-containing chemotherapy and whose tumours express PD-L1 with a $\geq 1\%$ TPS. If EGFR or ALK genomic tumour aberration, After one line of targeted therapy
	Keytruda solution for infusion vial 4ml	Locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 with a $\geq 1\%$ tumour proportion score (TPS) no EGFR or ALK genomic tumour aberrations, as monotherapy, and first line
	Tagrisso	Locally advanced or metastatic non-small cell lung cancer (NSCLC) as second line therapy (after EGFR TKI therapy) and EGFR T790M mutation-positive
	Tagrisso	Locally advanced or metastatic non-small cell lung cancer (NSCLC) as first line therapy and (EGFR) exon 19 deletions or exon 21 (L858R) positive
	Tagrisso	Non-small cell lung cancer adjuvant therapy after tumor resection in adult patients with tumors having (EGFR) exon 19 deletions or exon 21 L858R mutations.
	Xalkori	Advanced non-small cell lung carcinoma (NSCLC) whose tumours are ALK positive and as first line therapy or second line therapy after failure of systemic chemotherapy
Malignant Melanoma	Yervoy solution for infusion 10ml vial	Advanced (unresectable or metastatic) malignant melanoma
	Yervoy solution for infusion 40ml vial	

	Keytruda solution for infusion vial 4ml	Adjuvant malignant melanoma and with lymph node involvement and following complete resection
	Keytruda solution for infusion vial 4ml	Advanced (unresectable or metastatic) malignant melanoma Stage IIB or IIC Melanoma
	Keytruda solution for infusion vial 4ml	Adults and adolescents aged 12 years and above Adjuvant therapy Monotherapy
Multiple Myeloma	Darzalex solution for infusion vial 20ml	Multiple myeloma and after at least three prior lines of therapy (including a proteasome inhibitor and immunomodulatory agent) or who are double refractory to PI and immunomodulatory agent
	Darzalex solution for infusion vial 5ml	
	Darzalex solution for injection 15ml vial	
	Darzalex solution for infusion vial 20ml	Newly diagnosed myeloma, and ineligible for autologous stem cell transplant (ASCT), in combination with bortezomib, melphalan and prednisone
	Darzalex solution for infusion vial 5ml	
	Darzalex solution for injection 15ml vial	
	Darzalex solution for infusion vial 20ml	Newly diagnosed myeloma, and ineligible for autologous stem cell transplant (ASCT), in combination with lenalidomide and dexamethasone
	Darzalex solution for infusion vial 5ml	
	Darzalex solution for injection 15ml vial	
	Darzalex solution for infusion vial 20ml	Newly diagnosed myeloma, and ineligible for autologous stem cell transplant (ASCT), in combination with bortezomib, thalidomide and dexamethasone
	Darzalex solution for infusion vial 5ml	
	Darzalex solution for injection 15ml vial	
	Darzalex solution for infusion vial 20ml	Multiple myeloma, treatment of relapsed/refractory disease, in combination with bortezomib and dexamethasone in adult patients
	Darzalex solution for infusion vial 5ml	

	Darzalex solution for injection 15ml vial	
	Darzalex solution for infusion vial 20ml	Multiple myeloma, treatment of relapsed/refractory disease, in combination with lenalidomide and dexamethasone in adult patients
	Darzalex solution for infusion vial 5ml	
	Darzalex solution for injection 15ml vial	
Chronic Lymphocytic Leukemia	Imbruvica	Chronic Lymphocytic Leukaemia and as first line therapy or treatment for relapsed (refractory) disease
	Venclexta 4x7 day wallet	Chronic lymphocytic leukemia in combination with obinituzumab and as first line therapy
	Venclexta	
	Venclexta 4x7 day wallet	Chronic lymphocytic leukemia in combination with rituximab and after at least one prior therapy
	Venclexta	
	Calquence	Relapsed or Refractory Chronic Lymphocytic Leukemia
	Calquence®	Chronic Lymphocytic Leukaemia and as first line therapy or treatment for relapsed (refractory) disease
	Brukinsa®	Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, without Del 17p mutation as first line therapy
Brukinsa®	Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Relapsed/Refractory	
Waldenstrom Macroglobulinemia	Imbruvica	Waldenstrom Macroglobulinemia as first line therapy or relapsed disease and after treatment with a rituximab-containing regimen
	Brukinsa®	Waldenstrom Macroglobulinemia as first line therapy or relapsed disease after ≥1 prior line of therapy
T-cell Lymphoma	Adcetris powder for reconstitution vial	Cutaneous T-cell Lymphoma and in combination with Doxorubicin,

		Cyclophosphomide and Prednisone and previously treated (relapsed disease) and CD-30 positive
	Adcetris powder for reconstitution vial	Cutaneous T-cell Lymphoma and in combination with Doxorubicin, Cyclophosphomide and Prednisone and as first line therapy and CD-30 positive
	Adcetris powder for reconstitution vial	Systemic anaplastic large cell lymphoma (sALCL)
Hodgkin's Lymphoma	Adcetris powder for reconstitution vial	Hodgkin's lymphoma and as consolidation therapy after autologous stem-cell transplantation and at risk of relapse or progression
	Keytruda solution for infusion vial 4ml	Classical Hodgkin lymphoma, and failed autologous stem cell transplant (ASCT), or following at least two prior therapies when ASCT is not a treatment option
Renal Cell Carcinoma	Lenvima	Advanced renal cell carcinoma (RCC) and in combination with everolimus and after one prior antiangiogenic therapy
	Keytruda solution for infusion vial 4ml	Advanced renal cell carcinoma (RCC) as first line treatment, and in combination with axitinib
	Keytruda solution for infusion vial 4ml	Advanced renal cell carcinoma, and as first line therapy, and in combination with lenvatinib
	Keytruda® solution for infusion vial 4ml	Adjuvant treatment in Renal Cell Carcinoma as monotherapy, at intermediate-high or high risk of recurrence following nephrectomy
	Cabometyx	Advanced renal cell carcinoma 2nd line (following prior vascular endothelial growth factor targeted therapy) As monotherapy

Metastatic Head and Neck Squamous Cell Carcinoma	Keytruda solution for infusion vial 4ml	Head and neck squamous cell carcinoma (HNSCC), as first line treatment, and in combination with platinum and 5-fluorouracil (5-FU) CPS $\geq$ 1
	Keytruda solution for infusion vial 4ml	Head and neck squamous cell carcinoma (HNSCC), as first line treatment, and monotherapy, or CPS $\geq$ 20
	Keytruda solution for infusion vial 4ml	HNSCC with disease progression on or after platinum containing chemotherapy, as monotherapy in adults whose tumours express PD-L1 with a $\geq$ 50% TPS
Metastatic Colorectal Cancer	Keytruda solution for infusion vial 4ml	Unresectable or metastatic colorectal cancer, with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and as first line treatment
Metastatic Ovarian Cancer	Lynparza	Epithelial ovarian, fallopian tube or primary peritoneal cancer, with a mutation in BRCA1, BRCA2, or both complete response or partial response, to first line platinum-based chemotherapy as monotherapy
	Lynparza	Epithelial ovarian, fallopian tube or primary peritoneal cancer, platinum sensitive relapsed, with a mutation in BRCA1, BRCA2, or both complete response or partial response, to first line platinum-based chemotherapy as monotherapy
Acute Myeloid Leukemia	Venclexta 4x7 day wallet	Acute Myeloid Leukemia $\geq$ 75 or not eligible for intensive chemotherapy in combination with LDAC
	Venclexta	
	Venclexta 4x7 day wallet	Acute Myeloid Leukemia, $\geq$ 18 previously untreated patients, and
	Venclexta	

		ineligible for intensive chemotherapy in combination with Azacitidine
Metastatic triple-negative breast cancer	Keytruda solution for infusion vial 4ml	Locally recurrent unresectable or metastatic triple-negative breast cancer, in adults whose tumours express PD-L1 with a CPS $\geq$ 10.
Early-stage Triple-negative Breast cancer	Keytruda solution for infusion vial 4ml	Early-stage triple-negative breast cancer in combination with chemotherapy as neo-adjuvant therapy then monotherapy as adjuvant
Oesophageal and gastro-oesophageal junction cancer	Keytruda solution for infusion vial 4ml	Locally advanced unresectable or metastatic carcinoma of the oesophagus, or HER2-negative gastro-oesophageal junction adenocarcinoma, previously untreated patients, and in combination with platinum and 5-fluorouracil (5-FU) in adults whose tumours express PD-L1 with a CPS $\geq$ 10.
	Keytruda®	Locally advanced unresectable or metastatic, carcinoma of the oesophagus, or gastro-oesophageal junction, in combination with platinum and fluoropyrimidine based chemotherapy as first line, in patients whose tumours express PD-L1 with a CPS $\geq$ 10
	Keytruda®	Locally advanced unresectable or Metastatic gastric, and HER2-negative gastro-oesophageal junction adenocarcinoma, whose tumours express PD-L1 with a CPS $\geq$ 10
	Keytruda®	Locally advanced unresectable or metastatic, HER2-negative gastric or gastro-oesophageal junction

		adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, as first line, in patients whose tumours express PD-L1 with a CPS $\geq$ 10
Endometrial Carcinoma	Keytruda solution for infusion vial 4ml	Advanced or recurrent endometrial carcinoma in adults with disease progression on or, following prior treatment with platinum containing therapy in any setting in combination with lenvatinib, and who are not candidates for curative surgery or radiation
	Keytruda solution for infusion vial 4ml	Advanced or recurrent endometrial carcinoma, and not candidate of curative surgery or radiation, in combination with lenvatinib, and following prior treatment with a platinum-containing therapy
Metastatic Prostate Cancer	Lynparza®	Metastatic castration-resistant prostate cancer with a homologous recombination repair gene mutation, as monotherapy, and following prior hormone agent
	Lynparza	
Adjuvant non-small cell lung cancer	Tagrisso®	Adjuvant non-small cell lung cancer (NSCLC), and EGFR - exon 19 deletions or exon 21 (L858R) positive, first line therapy, as monotherapy
Metastatic Cervical Cancer	Keytruda solution for infusion vial 4ml	Metastatic Cervical Cancer, in tumors expressing PD-L1 and with a CPS $\geq$ 1 In combination with chemotherapy with or without Bevacizumab As first line treatment
Gastrointestinal stromal tumor	Stivarga®	Locally advanced, unresectable or metastatic gastrointestinal stromal tumor 2nd line (following prior

		matinib mesylate and sunitinib malate) As monotherapy
Early Non-Small Cell Lung Cancer	Keytruda®	Neo-adjuvant NCSLC, and stage II, IIIA, or IIIB (T3 4N2) resectable in combination with platinum-based chemotherapy
	Keytruda®	Adjuvant NCSLC, and stage IB (T2a $\geq$ 4 cm), II, or IIIA, and PD-L1 TPS between 1% and 49% as monotherapy
Mantle Cell Lymphoma	Imbruvica	Mantle cell lymphoma (MCL) and after treatment with at least one prior therapy

## Oncology Pharmacy Designated Service Provider (DSP)

### Medicine administered in-rooms

Medicine administered in the doctor's rooms, such as injectable and infusional chemotherapy, should be obtained from a courier DSP (Network 276) indicated below:

- Dis-Chem's Oncology Courier Pharmacy
- Qestmed
- Olsens Pharmacy (practice no: 6002226)
- Medipost Pharmacy.

All oncology-related medicines (for in-rooms treatment) obtained through other service providers will be subject to a 20% co-payment.

### Medicine scripted and dispensed at a retail pharmacy

Oncology and oncology-related medicine (like supportive medicine, oral chemotherapy and hormonal therapy) will be covered in full at MedXpress or any MedXpress Network Pharmacy indicated below:

- Dis-Chem's Oncology Courier Pharmacy
- Medipost Pharmacy
- Qestmed.

Scripted medicines for oncology obtained from all other retail pharmacies will be subject to a 20% co-payment.

## **Oncology treatment Designated Service Provider (DSP)**

The South African Oncology Consortium (SAOC) has a vast network of oncology healthcare professionals available to treat you and is the Scheme's DSP.

The healthcare professionals on the SAOC Network will be able to deliver in- and out-of-hospital radiation and chemotherapy treatment for solid tumours only for newly diagnosed patients registering for the first time for oncology treatment, this treatment will be covered in full up to the agreed rates. This excludes haematology and paediatric oncology.

If you use a cancer specialist who is not in the SAOC Network, the Scheme will pay up to an agreed tariff, and you need to pay the balance.

## **Complaints process**

You may lodge a complaint or query with Netcare Medical Scheme directly on 0861 638 633 or address a complaint in writing to the Principal Officer at the Scheme's registered address. Should your complaint remain unresolved, you may lodge a formal dispute by following the Netcare Medical Scheme internal disputes process.

You may, as a last resort, approach the Council for Medical Schemes for assistance.

Council for Medical Schemes Complaints Unit, Block A, Eco Glades 2 Office Park, 420 Witch-Hazel Avenue, Eco Park, Centurion, 0157 / 0861 123 267 / [complaints@medicalschemes.co.za](mailto:complaints@medicalschemes.co.za) / [www.medicalschemes.co.za](http://www.medicalschemes.co.za)